Ligand’s Chief Operating Officer Matt Foehr will discuss Ligand’s research and development model, highlighting the ability of Captisol ® to serve as a platform for growth due to the pharmaceutical industry’s increasing need for formulation solubility and stability, and illustrating that:
- Captisol can make new drugs possible, and can make existing drugs better, by enhancing their delivery characteristics.
- Ligand's Captisol-based royalties are well positioned for growth with the recent approval of Kyprolis, and potential new products like The Medicines Company’s MDCO-157 (Captisol-enabled clopidogrel), Lundbeck's carbemazepine, and Rib-X's delafloxacin advancing through or toward late-stage development.
- Ligand is entitled to royalties on Merck’s lead BACE inhibitor compound for Alzheimer’s disease. Merck has reported single doses are associated with up to a 92% mean reduction of beta amyloid levels from baseline. Merck announced the initiation of a Phase 2/3 clinical trial on December 3rd.
- Ligand is entitled to milestones and royalties for dinaciclib, for which Merck recently initiated a Phase 2b/3 study for chronic lymphocytic leukemia.
- Pfizer expects a decision from the European Medicines Agency in 2013 regarding Aprela for the treatment of symptoms associated with menopause and the prevention of osteoporosis.
- Ligand is initiating a pivotal trial for Captisol-enabled melphalan (LGD-353) for the treatment of multiple myeloma.
- GlaxoSmithKline recently received approval for Promacta treatment of thrombocytopenia in patients with chronic hepatitis C and is pursuing development for Promacta in oncology-related indications.